PLANET® Dose用于[177Lu]Lu-DOTA-TATE剂量评估的临床实施:与Dosimetry Toolkit®及OLINDA/EXM® V1.0的比较
该研究在体模和21例神经内分泌肿瘤患者中比较了PLANET® Dose与本科室现行剂量学方法(GE Dosimetry Toolkit®联合OLINDA/EXM® V1.0)在[177Lu]Lu-DOTA-TATE治疗后器官吸收剂量(AD)的量化差异。结果显示两种方法获得的器官质量、时间积分活度系数(TIAC)和AD一致性良好,Lin一致性相关系数为0.99,支持PLANET® Dose用于临床常规患者剂量学评估。
要点
- PLANET® Dose与现行方法获得的器官AD一致性良好,Lin一致性相关系数为0.99。
- 图像配准和器官分割步骤对AD差异的影响大于剂量学计算方法本身。
- 结果支持PLANET® Dose用于[177Lu]Lu-DOTA-TATE治疗后的临床常规剂量学评估。
核心结论
- PLANET® Dose获得的危及器官AD与现行软件计算结果一致,并与文献相符,验证了其临床常规使用。
研究设计与样本
- 体模评估SPECT校准因子随时间变化并比较两种方法获得的TIAC。
- 21例神经内分泌肿瘤患者在第1次和第2次注射7.2 ± 0.2 GBq [177Lu]Lu-DOTA-TATE后行剂量学分析,每种软件各40次分析。
- SPECT/CT于注射后4 h、24 h、72 h和192 h采集,使用Xeleris软件重建。
- 用Dosimetry Toolkit®(DTK)和PLANET® Dose测定肝、脾、肾质量和TIAC。
- AD分别用OLINDA/EXM® V1.0及PLANET® Dose的局部沉积法(LDM)或剂量体素-核卷积(DK)计算。
主要发现
- 体模中3D校准因子随时间仅有轻微变化(0.8%和3.3%),DTK和PLANET® Dose获得的TIAC分别为225.19 h和217.52 h。
- 患者中器官质量的均方根偏差为8.9%,TIAC为8.1%,LDM和DK计算的AD分别为9.1%和7.8%。
- Lin一致性相关系数为0.99;Bland-Altman分析显示95%的40次肝、肾、脾剂量学分析中AD差值分别介于-0.75至0.49 Gy、-0.20至0.64 Gy和-0.43至1.03 Gy。
- 与图像配准和器官分割步骤相比,剂量学方法对AD差异的影响较小。
临床怎么用
- 可在临床常规中采用PLANET® Dose对[177Lu]Lu-DOTA-TATE治疗患者进行危及器官剂量学评估。
- 应注意图像配准和器官分割步骤对AD差异的影响大于剂量学计算方法本身。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of this study was to compare a commercial dosimetry workstation (PLANET® Dose) and the dosimetry approach (GE Dosimetry Toolkit® and OLINDA/EXM® V1.0) currently used in our department for quantification of the absorbed dose (AD) to organs at risk after peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. METHODS: An evaluation on phantom was performed to determine the SPECT calibration factor variations over time and to compare the Time Integrated Activity Coefficients (TIACs) obtained with the two approaches. Then, dosimetry was carried out with the two tools in 21 patients with neuroendocrine tumours after the first and second injection of 7.2 ± 0.2 GBq of [177Lu]Lu-DOTA-TATE (40 dosimetry analyses with each software). SPECT/CT images were acquired at 4 h, 24 h, 72 h and 192 h post-injection and were reconstructed using the Xeleris software (General Electric). The liver, spleen and kidneys masses and TIACs were determined using Dosimetry Toolkit® (DTK) and PLANET® Dose. The ADs were calculated using OLINDA/EXM® V1.0 and the Local Deposition Method (LDM) or Dose voxel-Kernel convolution (DK) on PLANET® Dose. RESULTS: With the phantom, the 3D calibration factors showed a slight variation (0.8% and 3.3%) over time, and TIACs of 225.19 h and 217.52 h were obtained with DTK and PLANET® Dose, respectively. In patients, the root mean square deviation value was 8.9% for the organ masses, 8.1% for the TIACs, and 9.1% and 7.8% for the ADs calculated with LDM and DK, respectively. The Lin's concordance correlation coefficient was 0.99 and the Bland-Altman plot analysis estimated that the AD value difference between methods ranged from - 0.75 to 0.49 Gy, from - 0.20 to 0.64 Gy, and from - 0.43 to 1.03 Gy for 95% of the 40 liver, kidneys and spleen dosimetry analyses. The dosimetry method had a minor influence on AD differences compared with the image registration and organ segmentation steps. CONCLUSIONS: The ADs to organs at risk obtained with the new workstation PLANET® Dose are concordant with those calculated with the currently used software and in agreement with the literature. These results validate the use of PLANET® Dose in clinical routine for patient dosimetry after targeted radiotherapy with [177Lu]Lu-DOTA-TATE.
引用
- Santoro L, Pitalot L, Trauchessec D, et al. Clinical implementation of PLANET® Dose for dosimetric assessment after [177Lu]Lu-DOTA-TATE: comparison with Dosimetry Toolkit® and OLINDA/EXM® V1.0. EJNMMI Res. 2021. PMID: 33394212. doi:10.1186/s13550-020-00737-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。